Discovery Sciences, Novartis Biomedical Research, Cambridge, Massachusetts 02139, United States.
Global Discovery Chemistry, Novartis Biomedical Research, Emeryville, California 94608, United States.
J Med Chem. 2024 Oct 10;67(19):17454-17471. doi: 10.1021/acs.jmedchem.4c01404. Epub 2024 Sep 27.
The COVID-19 pandemic highlights the ongoing risk of zoonotic transmission of coronaviruses to global health. To prepare for future pandemics, it is essential to develop effective antivirals targeting a broad range of coronaviruses. Targeting the essential and clinically validated coronavirus main protease (M), we constructed a structurally diverse M panel by clustering all known coronavirus sequences by M active site sequence similarity. Through screening, we identified a potent covalent inhibitor that engaged the catalytic cysteine of SARS-CoV-2 Mpro and used structure-based medicinal chemistry to develop compounds in the pyrazolopyrimidine sulfone series that exhibit submicromolar activity against multiple M homologues. Additionally, we solved the first X-ray cocrystal structure of M from the human-infecting OC43 coronavirus, providing insights into potency differences among compound-target pairs. Overall, the chemical compounds described in this study serve as starting points for the development of antivirals with broad-spectrum activity, enhancing our preparedness for emerging human-infecting coronaviruses.
新型冠状病毒肺炎疫情凸显了冠状病毒向全球健康传播的持续风险。为了为未来的大流行做准备,开发针对广泛冠状病毒的有效抗病毒药物至关重要。针对重要且经临床验证的冠状病毒主要蛋白酶(Mpro),我们通过按 M 活性位点序列相似性对所有已知的冠状病毒序列进行聚类,构建了一个结构多样的 Mpro 结构域库。通过筛选,我们鉴定出一种有效的共价抑制剂,该抑制剂与 SARS-CoV-2 Mpro 的催化半胱氨酸结合,并使用基于结构的药物化学方法开发出一系列吡唑并嘧啶磺酰胺类化合物,对多种 M 同源物具有亚微摩尔的活性。此外,我们解析了第一个来自人感染 OC43 冠状病毒的 Mpro 的 X 射线共晶结构,为化合物-靶标对之间的效力差异提供了见解。总之,本研究中描述的化学化合物可作为开发具有广谱活性的抗病毒药物的起点,增强我们对新兴人感染冠状病毒的准备。